» Articles » PMID: 32633824

Putative Cut-Points in Sarcopenia Components and Incident Adverse Health Outcomes: An SDOC Analysis

Abstract

Objectives: Analyses performed by the Sarcopenia Definitions and Outcomes Consortium (SDOC) identified cut-points in several metrics of grip strength for consideration in a definition of sarcopenia. We describe the associations between the SDOC-identified metrics of low grip strength (absolute or standardized to body size/composition); low dual-energy x-ray absorptiometry (DXA) lean mass as previously defined in the literature (appendicular lean mass [ALM]/ht ); and slowness (walking speed <.8 m/s) with subsequent adverse outcomes (falls, hip fractures, mobility limitation, and mortality).

Design: Individual-level, sex-stratified pooled analysis. We calculated odds ratios (ORs) or hazard ratios (HRs) for incident falls, mobility limitation, hip fractures, and mortality. Follow-up time ranged from 1 year for falls to 8.8 ± 2.3 years for mortality.

Setting: Eight prospective observational cohort studies.

Participants: A total of 13,421 community-dwelling men and 4,828 community-dwelling women. MEASUREMENTS Grip strength by hand dynamometry, gait speed, and lean mass by DXA.

Results: Low grip strength (absolute or standardized to body size/composition) was associated with incident outcomes, usually independently of slowness, in both men and women. ORs and HRs generally ranged from 1.2 to 3.0 for those below vs above the cut-point. DXA lean mass was not consistently associated with these outcomes. When considered together, those who had both muscle weakness by absolute grip strength (<35.5 kg in men and <20 kg in women) and slowness were consistently more likely to have a fall, hip fracture, mobility limitation, or die than those without either slowness or muscle weakness.

Conclusion: Older men and women with both muscle weakness and slowness have a higher likelihood of adverse health outcomes. These results support the inclusion of grip strength and walking speed as components in a summary definition of sarcopenia. J Am Geriatr Soc 68:1429-1437, 2020.

Citing Articles

BIO101 in Sarcopenic Seniors at Risk of Mobility Disability: Results of a Double-Blind Randomised Interventional Phase 2b Trial.

Fielding R, Dao M, Cannon K, Desvarieux M, Miller S, Gimness M J Cachexia Sarcopenia Muscle. 2025; 16(2):e13750.

PMID: 40026058 PMC: 11873539. DOI: 10.1002/jcsm.13750.


Dietary Patterns, Kidney Function, and Sarcopenia in Chronic Kidney Disease.

Kim J, Yang S Nutrients. 2025; 17(3).

PMID: 39940262 PMC: 11821004. DOI: 10.3390/nu17030404.


Supervised Machine Learning to Examine Factors Associated with Respiratory Sinus Arrhythmias and Ectopic Heart Beats in Adults: A Pilot Study.

Lahr P, Carling C, Nauer J, McGrath R, Grier J Hearts (Basel). 2025; 5(3):275-287.

PMID: 39897455 PMC: 11784985. DOI: 10.3390/hearts5030020.


Fractures in sub-Saharan Africa: epidemiology, economic impact and ethnography (Fractures-E ): study protocol.

Burton A, Drew S, Cassim B, Jarjou L, Gooberman-Hill R, Noble S Wellcome Open Res. 2025; 8():261.

PMID: 39822313 PMC: 11736110. DOI: 10.12688/wellcomeopenres.19391.1.


Exploring the association between pro-inflammatory mediators and sarcopenia in cancer patients through different diagnostic tools: a narrative review.

Cruz J, Pereira L, Steffens D, Vieira Carvalho A, Drummond-Lage A Ann Transl Med. 2025; 12(6):114.

PMID: 39817248 PMC: 11729810. DOI: 10.21037/atm-24-128.


References
1.
Bhasin S, Travison T, Manini T, Patel S, Pencina K, Fielding R . Sarcopenia Definition: The Position Statements of the Sarcopenia Definition and Outcomes Consortium. J Am Geriatr Soc. 2020; 68(7):1410-1418. DOI: 10.1111/jgs.16372. View

2.
Cawthon P, Peters K, Shardell M, McLean R, Dam T, Kenny A . Cutpoints for low appendicular lean mass that identify older adults with clinically significant weakness. J Gerontol A Biol Sci Med Sci. 2014; 69(5):567-75. PMC: 3991141. DOI: 10.1093/gerona/glu023. View

3.
Fielding R, Vellas B, Evans W, Bhasin S, Morley J, Newman A . Sarcopenia: an undiagnosed condition in older adults. Current consensus definition: prevalence, etiology, and consequences. International working group on sarcopenia. J Am Med Dir Assoc. 2011; 12(4):249-56. PMC: 3377163. DOI: 10.1016/j.jamda.2011.01.003. View

4.
Schaap L, Koster A, Visser M . Adiposity, muscle mass, and muscle strength in relation to functional decline in older persons. Epidemiol Rev. 2012; 35:51-65. DOI: 10.1093/epirev/mxs006. View

5.
Duchowny K, Peterson M, Clarke P . Cut Points for Clinical Muscle Weakness Among Older Americans. Am J Prev Med. 2017; 53(1):63-69. PMC: 5497994. DOI: 10.1016/j.amepre.2016.12.022. View